Founder & Chairman
Mori Arkin’s entrepreneurial journey began when he took over Agis, the pharmaceutical company founded by his late father, Ziama Arkin in 1961. Under Mori’s leadership, Agis grew into a global leader in topical generics and active pharmaceutical ingredients (API). In 2005, the company was sold to Perrigo, marking one of the largest M&A deals in Israel at the time.
With the capital from the sale, Mori established Arkin in 2009, with the vision of creating a professional and financial platform to drive pioneering developments in healthcare. This laid the foundation for a leading investment platform in the life sciences sector. His strategic insight positioned Arkin as a key player in healthcare investments, focusing on pharmaceuticals, biotechnology, and medical devices.
Since 2014, the next generation has taken over the leadership of the company, expanding Arkin’s investment strategy into real estate, equity, and technology. While Mori’s sons oversee the broader strategy, Mori continues to guide and advise the company, playing an active role in life sciences investments.
In addition to his role in life sciences, Mori serves on the boards of several companies beyond the sector, including Odysight, Sol-Gel Technologies, and Virility Medical, offering his expertise to support their growth.
Mori holds an undergraduate degree in Psychology from Tel Aviv University, where he also pursued studies at the Cohn Institute for the History and Philosophy of Science and Ideas. His research articles on Renaissance art, and particularly on Michelangelo were published in The Art Bulletin journal, PsyArt, and in the December 2024 issue of the Sixteenth Century Journal.
Together with his wife, Doris, Mori is also involved in philanthropy through the Arkin Family Foundation, which focuses on education, healthcare, and civil rights.
Let’s get in touch!
